| Patient | David Hume |
|---|---|
| Date of birth | 1711-05-07 |
| Identifiers | MRN HR-EN012-SYN-TD; SSN (made up) 000-12-3049 |
| Document date | 1775-10-19 |
| Author | Fiona Gallacher, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review after completing adjuvant chemotherapy; start of surveillance. [S]
Mr. Hume returns two weeks after the last capecitabine dose of his fourth and final CAPOX cycle. The DPYD genotype before cycle 1 showed no decreased-function variant, and he received all four cycles on schedule at full dose. In cycle 2 he had three days of loose stools, controlled with loperamide. His September cold resolved without complications. Cold-triggered tingling after each oxaliplatin dose has left mild numbness of the fingertips and toe tips that does not interfere with buttoning, writing, or walking, and is not painful. He has no bowel bleeding or change in habit, no abdominal pain, cough, or bone pain. He walks 30 minutes a day and writes every morning. He feels well and asks what the follow-up will be. [S]
| Element | Detail |
|---|---|
| Treatment | Four cycles of CAPOX completed at full dose |
| Toxicity | Grade 1 diarrhea in cycle 2; grade 1 sensory neuropathy; no hand-foot syndrome |
| Recurrence symptoms | None: no bleeding, change in bowel habit, pain, cough, or weight loss |
| Function | Walking 30 minutes a day; writing daily |
| Weight | 81.0 kg, down 1.5 kg since the postoperative visit |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Mild tiredness in the afternoons; no fever or night sweats |
| Gastrointestinal | Negative | Formed stools once or twice a day; no blood or pain |
| Respiratory | Negative | No cough or breathlessness |
| Musculoskeletal | Negative | No bone pain |
| Neurological | Positive | Numb fingertips and toe tips, not painful; no weakness or imbalance |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferric carboxymaltose 750 mg intravenous infusion, two doses one week apart | 750 mg IV once a week for two doses | Intravenous route | 1775-06-01 to 1775-06-08 | completed | S |
| Capecitabine 500 mg oral tablet, four tablets (1749 mg, 1000 mg/m²) by mouth twice daily on days 1 to 14 of each 21-day cycle, four cycles | Four tablets twice daily on days 1 to 14 of each 21-day cycle | Oral route | 1775-07-20 to 1775-10-04 | completed | S |
| Oxaliplatin 130 mg/m² (260 mg) intravenous infusion on day 1 of each 21-day cycle, four cycles | 260 mg IV on day 1 every 21 days | Intravenous route | 1775-07-20 to 1775-09-21 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea during chemotherapy | One tablet every 8 hours as needed for nausea | Oral route | 1775-07-20 to 1775-10-04 | completed | S |
| Loperamide 2 mg oral capsule, two capsules after the first loose stool, then one after each loose stool, no more than eight a day | As needed for diarrhea on capecitabine | Oral route | 1775-07-20 to 1775-10-04 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1775-10-19 | Body height | 178 | cm | S |
| 1775-10-19 | Body weight | 81 | kg | S |
| 1775-10-19 | Body mass index (BMI) [Ratio] | 25.6 | kg/m2 | S |
| 1775-10-19 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1775-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1775-10-19 | Heart rate | 76 | /min | S |
| 1775-10-19 | Respiratory rate | 14 | /min | S |
| 1775-10-19 | Body temperature | 36.6 | Cel | S |
| 1775-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1775-10-19 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 1.8 | ng/mL | <=3 ng/mL | Normal | S |
| 1775-10-19 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1775-10-19 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 89 | fL | 80-100 fL | Normal | S |
| 1775-10-19 | Leukocytes [#/volume] in Blood by Automated count | 5.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1775-10-19 | Neutrophils [#/volume] in Blood by Automated count | 2.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1775-10-19 | Platelets [#/volume] in Blood by Automated count | 128 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1775-10-19 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1775-10-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1770)/1.73 sq M | 93 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1775-10-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-55 U/L | Normal | S |
| 1775-10-19 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1775-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 1775-10-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Abdomen | Scars healed; soft; no mass or liver enlargement |
| Lymph nodes | No supraclavicular or inguinal nodes |
| Neurological | Reduced light touch at the fingertips and toe tips; vibration slightly reduced at the toes; proprioception, strength, ankle reflexes, and Romberg normal |
| Skin | Palms and soles normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the sigmoid colon, suspected at presentation and confirmed by colonoscopic biopsy; synthetic modern diagnosis linked to the documented 1775 bowel disorder and its retrospective interpretation as colon cancer | active | confirmed | C18.7 | S — Synthetic diagnosis confirmed by biopsy and resection in the modern episode; the historical diagnosis remains a retrospective interpretation (R). |
| Iron deficiency anemia from chronic blood loss from the colon tumor | active | confirmed | D50.0 | S — Synthetic finding echoing the documented 'hemorrhage in the upper part of the intestines'; no blood count from his lifetime exists. |
| Hemangioma of the liver, 9 mm, segment VI; incidental finding characterized by MRI, not a metastasis | active | confirmed | D18.03 | S — Synthetic incidental finding; it addresses, and does not confirm, the unverified suggestion of liver spread. |
| Acute viral upper respiratory infection during adjuvant chemotherapy, without fever or neutropenia; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
| Oxaliplatin-induced sensory peripheral neuropathy, grade 1, fingertips and toe tips, without functional impairment | active | confirmed | G62.0 | S — Synthetic expected toxicity of adjuvant oxaliplatin. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | CEA | Every 3 to 6 months for 2 years, then every 6 months to 5 years | Completed today | 1.8 ng/mL, normal |
| Laboratory | Blood count after chemotherapy | At the end of treatment | Completed today | Hemoglobin 12.8 g/dL, MCV 89 fL, white cells 5.2, neutrophils 2.9, platelets 128 |
| Laboratory | Kidney and liver function | At the end of treatment | Completed today | Creatinine 0.92 mg/dL, eGFR 93; ALT 31 U/L, bilirubin 0.7 mg/dL |
| Examination | History and physical examination | Every 3 to 6 months for 2 years | Completed today | No evidence of recurrence |
| Examination | Peripheral neuropathy (CIPN) | Every visit during and after oxaliplatin | Completed today | Grade 1 sensory neuropathy, not painful |
| Survey | Distress and depression screen (PHQ-2) | At each follow-up visit | Completed today | PHQ-2 score 0 |
| Survey | Fatigue | Every visit | Completed today | Mild afternoon tiredness; activity advised |
| Imaging | CT of the chest, abdomen, and pelvis | Every 6 to 12 months for 5 years | Due | In December, six months after surgery |
| Examination | Surveillance colonoscopy | One year after resection, then at three years, then every five years | Due | In June; the preoperative colonoscopy was complete |
| Medication safety | Duloxetine for painful neuropathy | If neuropathy is painful | Not indicated | Neuropathy is not painful |
| Referral | Genetic counseling | Once | Due | Appointment next month, after chemotherapy as he asked |
| Self-management | Survivorship care plan and lifestyle counseling | Within one year of treatment completion; lifestyle every visit | Completed today | Written plan given; 150 minutes of activity a week, a diet low in red and processed meat, alcohol at or below one drink a day |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version 4.2025 (2025); The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surveillance and Survivorship Care of Patients After Curative Treatment of Colon and Rectal Cancer (2021); American Cancer Society Colorectal Cancer Survivorship Care Guidelines (2015); CMID: Clinical Monitoring Intelligence Database, colorectal cancer and anemia monographs (2026)
Follow-up: Adult preventive visit later this month. CT in December. Surveillance visit with CEA and blood count in January. Next scheduled visit 1775-10-28: adult preventive visit. [S]